These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 30043873

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A, Straathof JW, Derijks LJ.
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [Abstract] [Full Text] [Related]

  • 4. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA.
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
    Stein R, Lee D, Leonard MB, Thayu M, Denson LA, Chuang E, Herskovitz R, Kerbowski T, Baldassano RN.
    Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
    [Abstract] [Full Text] [Related]

  • 8. IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.
    Kampa KC, Morsoletto DBG, Loures MR, Pissaia A, Nones RB, Ivantes CAP.
    Arq Gastroenterol; 2017 Dec; 54(4):333-337. PubMed ID: 28954041
    [Abstract] [Full Text] [Related]

  • 9. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.
    Choi SY, Kang B, Choe YH.
    Gut Liver; 2019 Sep 15; 13(5):541-548. PubMed ID: 30970435
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
    Novakovic V, Abdija S, Larsen PB, Fenger M, Gredal L, Jacobsen KK.
    Clin Biochem; 2019 Dec 15; 74():73-75. PubMed ID: 31669514
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
    Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y.
    Inflamm Bowel Dis; 2010 Nov 15; 16(11):1898-904. PubMed ID: 20310016
    [Abstract] [Full Text] [Related]

  • 16. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, Haberman Y, Shouval DS, Weintraub I, Eliakim R, Ben-Horin S, Weiss B.
    J Pediatr Gastroenterol Nutr; 2018 Oct 15; 67(4):507-512. PubMed ID: 29901557
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease.
    Gomes LEM, da Silva FAR, Pascoal LB, Ricci RL, Nogueira G, Camargo MG, Lourdes Setsuko Ayrizono M, Fagundes JJ, Leal RF.
    Clinics (Sao Paulo); 2019 Apr 08; 74():e824. PubMed ID: 30994711
    [Abstract] [Full Text] [Related]

  • 20. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
    Curci D, Lucafò M, Cifù A, Bramuzzo M, Martelossi S, Favretto D, De Pellegrin F, Fabris M, Vascotto F, Naviglio S, Ventura A, Stocco G, Decorti G.
    J Pediatr Gastroenterol Nutr; 2019 Oct 08; 69(4):474-479. PubMed ID: 31149938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.